Citigroup
TENX icon

Citigroup’s Tenax Therapeutics TENX Stock Holding History

Citigroup’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16 Hold
1
– – ﹤0.01% 5710
2025
Q4 		$12 Buy
+1
New +$9 ﹤0.01% 5802
2022
Q3 		– Sell
-8
Closed -$4K – 6311
2022
Q2 		$4K Buy
+8
New +$8.01K ﹤0.01% 5716
2016
Q2 		– Hold
0
– – – 7428
2016
Q1 		– Hold
0
– – – 7757
2015
Q4 		– Hold
0
– – – 7859
2015
Q3 		– Hold
0
– -$7K – 7706
2015
Q2 		– Hold
0
– – – 6640
2015
Q1 		– Hold
0
– – – 6613
2014
Q4 		– Hold
0
– – – 6555
2014
Q3 		– Hold
0
– – – 6230
2014
Q2 		– Hold
0
– – – 6133
2014
Q1 		– Hold
0
– – – 6349

Other funds holding TENX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citigroup's TENX Position: Q1 2026 in Review

Citigroup held its Tenax Therapeutics (TENX) position steady in Q1 2026 at 1 share worth $16. The position accounts for ﹤0.01% of the portfolio, ranked #5710.

Citigroup first reported a position in TENX in Q2 2022 and has held it in 3 quarters since. The position peaked at $4K in Q2 2022. 80 funds tracked by Wall St. Rank hold TENX as of Q1 2026.

  • Citigroup held 1 share of Tenax Therapeutics worth $16 as of Q1 2026.
  • Citigroup left its Tenax Therapeutics share count unchanged in Q1 2026.
  • Tenax Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5710 holding.
  • Citigroup first reported a position in Tenax Therapeutics in Q2 2022 and has held it in 3 quarters since.
  • Citigroup's Tenax Therapeutics position peaked at $4K in Q2 2022.
  • 80 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.